¤E¤Q¤G¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ¦å²G¬ì

(C) 1.¤@¦ì¯f¤H¦b¦í°|·í¤Ñ©Ò°µªº¦å²G©Ù¤ù¦p¹Ï©Ò¥Ü¡A½Ð°Ý¯f¤H³Ì¥i¯à¬O¦³¤U¦C¦óºØª¬ªp¡H
A.¥¨¥À¬õ¦å²y¡]megaloblastic¡^³h¦å
B.¦ÛÅé§K¬Ì©Ê·»¦å©Ê³h¦å
C.®ü¬v©Ê³h¦å
D.·L²Ó¦åºÞ¯fÅÜ©Ê¡]microangiopathic¡^·»¦å©Ê³h¦å
E.¿ò¶Ç©Ê²y§Î¬õ¦å²y¯g¡]spherocytosis¡^
 
(C) 2.¤@¦ì¯f¤H¦]¦å²G¬Û²§±`¡A°µ¤F°©Åè¬ï¨ëÀˬd¡Aµ²ªGÅã¥Ü°©Å褤ªÞ²Ó­M¦û¤F45¢H¡F³o¨ÇªÞ²Ó­M¤Æ¾Ç¬V¦âperoxidase¬°³±©Ê¡Anonspecific esterase¬°³±©Ê¡A§K¬Ì²Ó­M§Ü­ìÀˬdµ²ªG¦p¤U¡GCD2(-)¡ACD3(-)¡ACD10(-)¡ACD13(+)¡ACD19(-)¡ACD33(+)¡ACD41(-)¡C½Ð°Ý¦¹¯f¤Hªº¶EÂ_¬°¡G
A.Acute lymphoblastic leukemia ¡]ALL¡^¡AT-cell
B.ALL¡AB-cell
C.Acute myeloid leukemia¡]AML¡^¡Aminimally differentiated¡]¢Û0¡^
D.AML¡Amonocytic¡]M5¡^
E.AML¡Amegakaryoblastic¡]M7¡^
 
(A) 3.¤@¦ì°ü¤H©â¦åÀˬd®Éµo²{¦å¤pªO¬°26,000/£gl¡A¦å¬õ¯À¤Î¥Õ¦å²y¥¿±`¡C¦¹°ü¤H°£¤p»L¤W¦³»´·L·ï«C¥~µL¨ä¥L¥X¦å²{¶H¡A½Ð°Ý¤U¦C±Ô­z¦óªÌ¬O¿ù»~ªº¡H
A.¦¹°ü¤H¦³¤º¥X¦åªº¦MÀI¡A»Ý­n¿éª`¦å¤pªO¿@ÁY²G¡C
B.»Ý¸ß°Ý¥ÎÃÄ¥v¡A¦]¬°«Ü¦hÃĪ«¦ppenicillins, cephalosporinsµ¥¥i³y¦¨¦å¤pªO¼Æ¥Ø§C¤U¡C
C.¤j³¡¥÷ÃĪ«¤Þ°_ªº¦å¤pªO¼Æ¥Ø§C¤U¥i¦b°±ÃÄ7¦Ü10¤Ñ«á³vº¥¦^´_¡C
D.¨xµw¤Æ¯f¤H·|¦]¬°µÊŦ¸~¤j¦©¯d¸û¦h¦å¤pªO¦b¸Ì­±¡A¦Ó³y¦¨¦å¤¤¦å¤pªO¼Æ¥Ø­°§C¡C
E.Heparin³y¦¨¦å¤pªO§Cªº­ì¦]¡A¤j¦h¬O¦]¬°§ÜÃĪ«§ÜÅéªþµÛ¦b¦å¤pªO¤W¦Ó³y¦¨¡C
 
(D) 4.¤U¦C¦óºØ¯e¯f¡A­Y¹ï¤@¯ë¤ÆªvÀøµL®Ä®É¡A¥i¥H¨Ï¥ÎthalidomideªvÀø¡A¬ù30¢H¦Ü40¢Hªº¯f±w¨ä¯e¯f¥i¥H±o¨ì§ïµ½¡H
A.«æ©Ê«e°©Åè²Ó­M¥Õ¦å¯f
B.ºC©Ê°©Åè©Ê¥Õ¦å¯f
C.À±º©«¬¤j²Ó­M²O¤Ú½F
D.¦hµo©Ê°©Åè½F
E.°©Åè¼W¥Í¤£¨}¯g­Ô¸s
 
(B) 5.¤@¦ì58·³¯f¤H©â¦åµ²ªG¦p¤U¡GHb 5gm/dL, Hct 15¢H, WBC 1,300/£g¢Ú, ¨ä¤¤absolute neutrophils¬°470/£g¢Ú, platelet 1,500/£gl¡C°©ÅèÀˬdÅã¥Ü¬°¦A¥Í¤£¨}©Ê³h¦å¡A½Ð°Ý¹ï¦¹¯f¤H³Ì¾A¦XªºªvÀø¬°¡G
A.¤ä«ù©ÊÀøªk¤Î²§Åé°©Åè²¾´Ó
B.¤ä«ù©ÊÀøªk¤Îµ¹¤©§ÜT²Ó­M²y³J¥Õ¥[¤WÀôÌU¯À¤ÎÃþ©T¾J
C.¤ä«ù©ÊÀøªk¤ÎªA¥Î¨k©Ê¶Pº¸»X­l¥Íª«
D.¤ä«ù©ÊÀøªk¤ÎªA¥ÎÃþ©T¾J
E.¤ä«ù©ÊÀøªk
 
(B) 6.¤U¦C¦³Ãö²O¤Ú²Ó­M´c©Ê¯fªº±Ô­z¡A¦óªÌ¬O¿ù»~ªº¡H
A.ºC©Ê¢Ð²O¤Ú²Ó­M¥Õ¦å¯f¡]CLL¡^ªº²Ó­Mªí­±¦h·|ªí²{CD5§Ü­ì¡A¥i»P¥¿±`¢Ð²O¤Ú²Ó­M°Ï§O
B.B-CLL Rai¹s´Áªº¯f¤H¡]¥u¦³²O¤Ú²Ó­M¹L¦h¡AµL¨ä¥L¦å²y¡B¨x¡BµÊ²§±`¡^¡A³Ì¦n°µ¤Æ¾ÇªvÀø¡Aªv¡ªº¾÷·|«Ü¤j
C.Follicular lymphoma±`¦³¬V¦âÅ鲧±`t¡]14¡F18¡^
D.À±º©«¬¤j²Ó­M²O¤Ú½FªºªvÀø¥H¦X¨Ö¤Æ¾ÇªvÀø¬°¥D
E.­GªºMALT²O¤Ú½F¦h»PHelicobacter pylori¡]HP¡^·P¬V¦³Ãö¡A¥i¥H¥ÎÃIJM°£¦¹²Óµß±o¨ì²¬Â¡
 
(E) 7.¤U¦C¦³ÃöÃþ¦å¤Í¯f¡]von Willebrand disease¡^±`¨£ªº¹êÅç«Ç²§±`¡A¦óªÌ¬O¿ù»~ªº¡H
A.aPTT¡]activated partial thromboplastin time¡^©µªø
B.¥X¦å®É¶¡©µªø
C.vWF¡]von Willebrand factor¡^¡GAg¡]antigen¡^¿@«×¤U­°
D.Factor VIII¬¡©Ê¤U­°
E.vWF¡GRcoF¡]restocetin cofactor¡^¥¿±`
 
(A) 8.³y¦¨TRALI¡]transfusion-related acute lung injury¡^ªº­ì¦]¬O¤U¦C­þ¤@¶µ¡H
A.¿é¤Jªº¦å¼ß¤¤±a¦³°ª¿@«×§Ü¤HÃþ¥Õ¦å²y§Ü­ì¡]HLA¡^¤§§ÜÅé¡A»P¨ü¦åªÌªº¥Õ¦å²y§@¥Î¦Ó³y¦¨
B.¿é¤Jªº¦å¼ß¤¤±a¦³°ª¿@«×§Ü¬õ¦å²y§Ü­ì¤§§ÜÅé¡A»P¨ü¦åªÌªº¬õ¦å²y§@¥Î¦Ó³y¦¨
C.¨ü¦åªÌÅ餺¦³§ÜHLAªº§ÜÅé¡A»P¿é¤J¤§¦å²G¦¨¤À¤¤ªº¥Õ¦å²y§@¥Î¦Ó²£¥Í
D.¿é¤Jªº¦å²G¦¨¤À¤¤¦³·L¥Íª«¡A³y¦¨¨ü¦åªÌ¤ÏÀ³
E.¬°¤@ºØ²¾´ÓÅé§Ü±J¥D¤ÏÀ³
 
(E) 9.¤U¦C¦óªÌ¬O´c©Ê³h¦å¡]pernicious anemia¡^¯f¤H¥Í¤ÆÀˬd¥i¯à¥X²{ªº²{¶H¡H1. ¤j¦å²y©Ê³h¦å¡]macrocytic anemia¡^2. ¶¡±µÁx¬õ¯À¼W°ª¡]indirect hyperbilirubinemia¡^3. ¨Å»Ä²æ²BúC¡]lactate dehydrogenase, LDH¡^¼W°ª4. ¥Õ¦å²y¼Æ¥Ø´î¤Ö5. ¦å¤pªO¼Æ¥Ø´î¤Ö
A.1
B.1+3
C.1+2+3
D.1+4+5
E.1+2+3+4+5
 
(D) 10.¤U¦C¦óºØª¬ªp·|¤Þ°_thrombocytosis¡H1. ´c©Ê¯f2. ¥Òª¬¸¢¾÷¯à¤®¶i3. µÊŦ¤Á°£4. ·P¬V5. ¥X¦å
A.1+3
B.3+4
C.1+2+3
D.1+3+4+5
E.1+2+3+4+5
 


< ¤E¤Q¤G¦~«×¸ÕÃD¥Ø¿ý >